The difficulty in maintaining weight loss during obesity treatment may be caused by a counteracting neuroendocrine response. It has been proposed that leptin could be a regulator of this response. We examined the relations between leptin levels during an initial very low calorie diet, other simultaneous endocrine changes, and the 1-yr weight reduction. Sixty-nine obese (24 men and 45 women) were treated with very low calorie diet for 16 weeks, followed by a hypocaloric diet for 32 weeks. Serum levels of leptin, insulin, cortisol, and thyroid hormones were measured at weeks 0, 8, and 18. The relative weight reductions after 18 and 48 weeks were 20.1% and 14.4% in men and 15.4% and 11.8% in women. Low initial leptin levels and large declines in serum leptin were associated with a large 1-yr weight loss in both genders. Leptin levels (baseline or changes) were not independently associated with the changes in insulin, cortisol, or thyroid hormones. Our results may indicate that leptin by itself could be of minor importance for the neuroendocrine response to severe caloric restriction in humans. (J Clin Endocrinol Metab 84: 4197-4203, 1999) 
weight reductions after 18 and 48 weeks were 20.1% and 14.4% in men and 15.4% and 11.8% in women. Low initial leptin levels and large declines in serum leptin were associated with a large 1-yr weight loss in both genders. Leptin levels (baseline or changes) were not independently associated with the changes in insulin, cortisol, or thyroid hormones. Our results may indicate that leptin by itself could be of minor importance for the neuroendocrine response to severe caloric restriction in humans. (J Clin Endocrinol Metab 84: [4197] [4198] [4199] [4200] [4201] [4202] [4203] 1999) L EPTIN IS believed to act as an afferent signal from adipose tissue to the brain, as part of a negative feedback loop regulating the size of the adipose tissue mass (1) . During evolution, food shortage has dominated over the risk of obesity, and the ability to adapt physiologically to starvation has been of vital importance. It has therefore been proposed that leptin might act primarily as a signal of starvation rather than obesity (2, 3) . Scarcity of food elicits a pattern of endocrine changes, including reduced fertility, decreased thyroid activity, and increased secretion of adrenal stress hormones, enhancing the chances of survival (2, 3) . In rodents, leptin is an important regulator of the neuroendocrine starvation response. Leptin-deficient mice (ob/ob) have abnormalities in the endocrine system that mimic those present during starvation (1) . Furthermore, administration of leptin to ob/ob mice (1) or to starved mice (2) blunts these changes. Less is known about leptin in relation to severe caloric restriction in humans.
It is a notorious problem in the treatment of obesity that, almost regardless of treatment strategy, it is difficult to maintain weight losses long term (4, 5) . One reason for this could be that severe caloric restriction may trigger a starvation response, including a neuroendocrine adaptation, that counteracts the therapeutic efforts (6, 7) . It could be hypothesized that the obese patients that show the most marked reductions in leptin levels during treatment would be at a greater risk for weight relapse (1, 8) .
We conducted a 1-yr dietary intervention in obese subjects, including 16 initial weeks of a very low calorie diet (VLCD). We examined the predictive value of the baseline level and short term changes in serum leptin for the 1-yr weight reduction. Furthermore, the change in serum leptin levels during the VLCD phase was examined in relation to changes in body weight and serum levels of insulin, cortisol, and thyroid hormones.
Subjects and Methods

Patients and treatment
Patients examined at the Clinical Metabolic Laboratory at Sahlgrenska University Hospital from January 1996 were invited to participate in a randomized, 2-yr obesity treatment program if aged 18 -60 yr and with a body mass index (BMI) Ն 30.0 kg/m 2 . The study was approved by the ethics committee of the Faculty of Medicine, University of Gö teborg, and all patients gave written informed consent.
The patients were randomized to two treatment groups. However, all subjects started with a 16-week VLCD, using Modifast (NOVARTIS Nutrition, Bern, Switzerland) and were recommended an intake of about 450 kcal/day. After the VLCD period, ordinary food was gradually introduced during a 3-week refeeding phase. All patients were then advised to consume an individualized hypocaloric diet (approximately Ϫ500 kcal/day) for up to 2 yr. According to the initial randomization, patients in group I were scheduled to repeat VLCD periods 2 weeks every third month. Patients in group II were to use VLCD whenever the body weight was above an individualized cut-off level, corresponding to the body weight after 16 weeks of VLCD treatment plus 3 kg. The cut-off was lowered after any further weight loss. In case of weight gain, the cut-off level remained unchanged. The results of the 2-yr trial will be reported separately, once finalized.
Twenty-four men and 45 women, free from drug treatment for diabetes or hypothyreosis, who all completed the initial treatment year, were available for the present 1-yr substudy. Among these 69 subjects, there were no differences between the 2 treatment groups in age, sex distribution, baseline levels of BMI and serum leptin, or the weight change during the first year. Thus, for the purpose of this report the treatment groups were not separated.
Measurements
Weight was measured to the nearest 0.1 kg using electronic scales calibrated monthly. Height was determined to the nearest 0.01 m. The total adipose tissue mass (kilograms) was estimated using previously published and validated anthropometric equations (9, 10) . At baseline and after 8 and 18 weeks the following serum levels were analyzed: leptin; insulin; cortisol; TSH; free and total T 4 (fT 4 and TT 4 ); and free, total and rT 3 (fT 3 , TT 3 , and rT 3 ). The serum concentrations of leptin were determined in duplicate using a human leptin RIA (Linco Research, Inc., St. Charles, MO) at Research Center for Endocrinology and Metabolism; all other analyses were performed at the Department of Clinical Chemistry, Sahlgrenska University Hospital. The laboratory is accredited according to European norm, EN 45 001. All patients had fasted overnight before blood sampling. Baseline characteristics of the study patients are shown in Table 1 .
Statistics
The change in a given variable (⌬) was calculated by subtracting the baseline value from a subsequent value (a decline thus becoming negative). Male sex was coded as 1, and female sex as 2. A paired t test was used to analyze changes in normally distributed variables, and for not normally distributed variables the Wilcoxon signed rank test was used. To compensate for multiple analyses performed on each variable, the ␣ level was decreased, so that ␣ was divided by the number of comparisons. Pearson product moment correlation coefficients (normally distributed variables) or Spearman rank correlation coefficients (not normally distributed variables) were calculated. Multiple linear regression analysis and two-way ANOVA (general linear model) were performed. The Minitab statistical package was used (Minitab, Inc., State College, PA). Figure 1 shows the relative change in body weight in response to caloric restriction. After the VLCD period, at week 16, the reduction in body weight was 20.3 Ϯ 6.7% (mean Ϯ sd) in men (P Յ 0.001) and 15.6 Ϯ 6.9% in women (P Յ 0.001). Between weeks 16 -18, body weight remained stable, with an average increase of 0.2 Ϯ 1.8 kg (P ϭ NS). The maintained weight losses after 48 weeks were 14.4 Ϯ 7.5% (P Յ 0.001) and 11.8 Ϯ 8.4% (P Յ 0.001) in men and women, respectively.
Results
Changes in body weight and hormone levels
The relative changes in the serum levels of leptin, insulin, cortisol, and thyroid hormones are shown in Fig. 2 . Compared to baseline there were highly significant reductions in the serum levels of leptin and insulin after both 8 and 18 weeks (P Յ 0.001). The cortisol levels were elevated on the same occasions, but to a significant extent only in women (P Յ 0.001). The changes in thyroid hormone levels showed similar patterns in both genders, with significant reductions in the TT 3 levels after both 8 (P Յ 0.001) and 18 weeks (P Յ 0.001 for women, P Յ 0.05 for men).
Prediction of weight reduction
The baseline leptin levels were not significantly correlated to the changes in body weight after 48 weeks in either men (r ϭ Ϫ0.09) or women (r ϭ Ϫ0.06). However, in a multivariate regression also taking sex, ⌬ leptin 18 , weight, and height into account ( Table 2 , Eq. I, all subjects), ⌬ weight 48 was positively related to baseline leptin as well as to ⌬ leptin 18 , but was negatively associated with baseline weight. This model indicated that a large maintained weight loss after 48 weeks (‚ weight 48 ) was associated with a low initial leptin level, a large decline in serum leptin after 18 weeks (‚ leptin 18 ), and a large body weight at baseline. Similar results were obtained when the model was applied to men and women separately ( Table  2 , Eq. I, men, and Eq. I, women).
As body weight can be measured with a fairly high precision, the negative relationship between baseline weight and ⌬ weight 48 was most likely real and only to a limited extent explained by a regression to the mean error. This is supported by the fact that when a median-split analysis was performed, we found patterns similar to those in Eq I (all subjects) among heavier as well as lighter subjects (not shown). When baseline levels and changes after 18 weeks in insulin, cortisol, or the thyroid hormones were added to the model, which was not feasible to do in men and women separately due to the groups being too small, no further significant associations were found (not shown). Using the baseline leptin/BMI ratio in Eq I instead of the separate values for height, weight, and leptin resulted in similar patterns in both genders. There were positive and highly significant relations between ⌬ weight 48 and the leptin/BMI ratio as well as ⌬ leptin 18 in both men and women (not shown).
When ⌬ weight 18 was added as a predictor (Eq II), the explanatory power of baseline leptin, body weight, and ⌬ leptin 18 disappeared. This was mainly related to the correlations between ⌬ weight 18 , on the one hand, and ⌬ leptin 18 (r ϭ 0.48 in men and r ϭ 0.60 in women), on the other. When ⌬ weight 48 was instead regressed by the 8-week changes, patterns similar to those in Table 2 were found. However, the explained variance of the model (Eq I) was reduced to about 28% in men and 9% in women (not shown).
Baseline body weight and leptin in relation to weight loss
In Fig. 3a , ⌬ weight 48 is shown as a function of the baseline leptin/BMI ratio and ⌬ leptin 18 . The leptin/BMI ratio was
Relative changes in the serum levels of leptin, insulin, cortisol, TSH, fT 4 , TT 4 , fT 3 , TT 3 , and rT 3 after 8 and 18 weeks of weight reduction in 24 men and 45 women as well as in all 69 subjects together. The mean Ϯ SD are shown (mean only in the all-subjects group). Filled squares, men; filled diamonds, women; open circles, all subjects. A paired t test or Wilcoxon signed rank test was used to test for differences vs. week 0. *, P Յ 0.05; **, P Յ 0.01; ***, P Յ 0.001. T-ratios of the indicated predictors and explained variances adjusted for degrees of freedom are shown. T-ratios Ն2.00, Ն2.65, and Ն3.44 are significant at the 0.05, 0.01, and 0.001 levels, respectively, for all subjects. The corresponding T-ratios are Ն2.06, Ն2.80, and Ն3.75 for men and Ն2.01, Ն2.69, and Ն3.52 for women.
divided at the median in a low and a high group, and ⌬ leptin 18 was similarly divided into one group with a small and one with a large decline, resulting in four groups of subjects (A-D). Subjects in group A had a ⌬ leptin 18 larger than the median and a leptin/BMI ratio below the median, whereas subjects in group B also had a ⌬ leptin 18 larger than the median but a leptin/BMI above the median. The subjects in group C had a ⌬ leptin 18 smaller than the median and a leptin/BMI ratio below the median, whereas subjects in group D also had a ⌬ leptin 18 smaller than the median but a leptin/BMI ratio above the median.
A low leptin/BMI ratio at baseline was associated with larger maintained weight losses after 48 weeks than a high ratio. Also, a large ⌬ leptin 18 was related to a larger ⌬ weight 48 than a small decline in leptin after 18 weeks. A two-way ANOVA showed that for ⌬ weight 48 there was a main effect of the baseline leptin/BMI ratio (F 3,65 ϭ 7.06; P Յ 0.01) and of ⌬ leptin 18 (F 3,65 ϭ 17.09; P Յ 0.001), but no significant interaction was found between the two factors (F 3,65 ϭ 0.95; P ϭ 0.33). Similar results were obtained when the analyses were based on the baseline leptin/total adipose tissue mass ratio or on the unadjusted baseline leptin level (not shown).
The baseline leptin levels were 32.6 Ϯ 6.2 ng/mL in group A, 57.8 Ϯ 22.2 ng/mL in group B, 24.2 Ϯ 8.1 ng/mL in group C, and 50.5 Ϯ 15.2 ng/mL in group D. The relative decline in serum leptin after 18 weeks were 75 Ϯ 10%, 64 Ϯ 16%, 41 Ϯ 25%, and 21 Ϯ 12%, respectively. Thus, among subjects with similar ⌬ leptin 18 [large (A and B) or small (C and D)], the largest relative decline in serum leptin were found among subjects with the lowest baseline leptin levels (A and C), also resulting in the lowest absolute serum leptin levels after 18 weeks in these two groups.
In Fig. 3b , ⌬ weight 48 is shown as a function of the baseline weight and the change in serum leptin after 18 weeks. Both body weight and ⌬ leptin 18 were divided at the median, resulting in four groups of subjects (E-H). In analogy with Eq I in Table 2 , a baseline body weight above the median was related to a larger ⌬ weight 48 than a low initial weight. As in Fig. 3a , a large ⌬ leptin 18 was related to a large maintained weight reduction after 48 weeks. A two-way ANOVA indicated that for ⌬ weight 48 there was a main effect of ⌬ leptin 18 (F 3,65 ϭ 12.84; P Յ 0.001) and a strong tendency for a main effect of baseline weight (F 3,65 ϭ 3.87; P ϭ 0.054). There was no significant interaction between the two factors (F 3,65 ϭ 0.12; P ϭ 0.73).
A post-hoc analysis of the weight changes in groups A, B, C, and D in Fig. 3a showed that groups A and B had the largest weight reductions after both 18 and 48 weeks (Fig. 4) . Group A had the highest and group B the lowest baseline body weight. Groups C and D, with the smallest maintained weight reductions after 48 weeks, also experienced smaller 18-week weight losses and had intermediate baseline weights. Figure 5 illustrates that subjects in group A had larger BMI and lower leptin levels at baseline compared to group B, with an overlap in BMI but not in leptin. Groups C and D were distributed over the whole observed BMI range, with low baseline leptin levels in C and high levels in D, almost without any overlap. 
Leptin and changes in other endocrine variables
The change in serum leptin after 18 weeks was significantly correlated to ⌬ insulin 18 in women (r ϭ 0.30; P Յ 0.05) but not in men (r ϭ 0.30; P ϭ NS). There were no significant correlations between ⌬ leptin 18 and the 18-week changes in cortisol (r ϭ 0.16 and r ϭ Ϫ0.02) or TT 3 (r ϭ Ϫ0.25 and r ϭ 0.26) in men and women, respectively.
To examine whether ⌬ leptin 18 was independently related to the observed endocrine alterations (Fig. 2) , multivariate regression analysis was performed (Table 3) . ⌬ leptin 18 was not related to changes in TT 3 or cortisol. The insignificant contribution of ⌬ leptin 18 increased the explained variance only by 0.5-1.6%. However, ⌬ leptin 18 tended to be independently associated to ⌬ insulin 18 (P ϭ 0.06). The explained variance increased by 4.7% when adding ⌬ leptin 18 .
A large increase in serum cortisol was associated with a small decrease in insulin levels and a large decrease in serum TT 3 . Otherwise, no significant relations between changes in endocrine variables were found. However, sex was or tended to be a significant predictor of the 18-week changes in TT 3 , cortisol, and insulin. To recalculate the full models of Table  3 in men and women separately was not feasible, as the groups were too small. However, when ⌬ TT 3,18 , ⌬ cortisol 18 , or ⌬ insulin 18 was regressed by baseline leptin, ⌬ leptin 18 , baseline BMI, and ⌬ weight 18 in each gender separately, no significant associations were found between the dependant variables and baseline leptin or ⌬ leptin 18 (not shown).
Discussion
Reduction in adipose tissue mass results in adaptive changes that limit further depletion of energy stores and eventually promote weight regain (11) . The mechanisms regulating these changes have not been fully elucidated. Based on experiments in rodents it has been proposed that leptin plays a major role in regulating the neuroendocrine system to preserve energy stores in response to starvation (2, 3) . If applicable in man, this suggests that patients with marked reductions in leptin levels in response to severe caloric restriction, during obesity treatment, would be at greater risk for a poor final weight loss. This led us to analyze the predictive value of changes in serum leptin levels in response to a diet induced weight loss for long term weight reduction. In this study we obtained three unexpected findings. Patients with the largest drop in serum leptin levels after 8 and 18 weeks of dieting achieved the largest 1-yr weight reductions. Furthermore, the largest maintained weight losses were observed in subjects with low baseline leptin levels and large baseline body weights. The predictive value of baseline leptin and baseline body weight were thus dissociated when regressed by the 1-yr weight reduction. Finally, associations between the changes in serum leptin levels and hormonal changes characteristic for a starvation response were weak, or even nonexistent.
Our observations suggest that reduced leptin levels in response to an energy deficit do not appear to regulate the hormonal starvation response in obese men and women and T-ratios of the indicated predictors and unadjusted explained variances are shown. T-ratios Ն2.00, Ն2.65, and Ն3.44 are significant at the 0.05, 0.01, and 0.001 levels, respectively. R 2 is given twice for each regression model, with and without ⌬ leptin 18 , to indicate the relative explanatory power of ⌬ leptin 18 .
do not predict weight relapse but, rather, a maintained weight reduction. This is in accordance with the report by Wing et al., who found no evidence that obese women with large initial reductions in leptin had difficulties in maintaining weight losses during a 6-month follow-up (12) . The fact that the maintained weight reduction after 1 yr was more strongly predicted by the early weight loss than by the early drop in serum leptin might suggest that the predictive power of the initial leptin decrease was mediated by the weight reduction. However, this suggestion must be confirmed with other types of experiments because the strong explanatory power of the early weight loss can be explained by a partwhole correlation. It should also be pointed out that a larger energy deficit in the heaviest subjects was not the sole explanation for large early weight reductions, as subjects in group B, with the second largest weight reduction at 18 weeks, had the lowest baseline body weight.
Our second finding was that on prediction of the maintained weight reduction, there was a difference between baseline body weight and baseline leptin. Thus, a large maintained weight reduction after 1 yr was associated with a large initial body weight, as expected. Although there was no significant simple correlation between ⌬ weight 48 and baseline leptin, low serum leptin levels at baseline were associated with a large ⌬ weight 48 in multivariate regressions. As we see it, the latter finding was not expected. Leptin is believed to be transported from the blood to the brain by a saturable transport system. Thus, the relationship between leptin in the cerebrospinal fluid (CSF) and in serum is curvilinear, with a small increase in CSF leptin concentration for any given increase in serum leptin at high serum leptin levels. The saturable leptin transport is reflected by low CSF/ serum leptin ratios in the obese (13, 14) and by an increased ratio after weight loss with a concomitant reduction in serum leptin levels (15) . A given serum leptin reduction in response to weight loss would consequently result in the smallest CSF leptin reductions in subjects with the highest serum leptin levels. Thus, a hypothalamic starvation response with accompanying weight relapse would be expected to be greatest in subjects with low serum leptin levels. In contrast, the largest maintained weight reductions were found in subjects with low serum leptin levels. In fact, many of these patients had serum leptin levels below the estimated level where the leptin transport becomes impaired (16) . Observational, longitudinal studies have found that baseline leptin levels correlate positively (17) , negatively (18, 19) , or not at all (20) with future weight change. In dietary intervention studies, Nicklas et al. found that the baseline leptin level was negatively correlated to the loss of fat after 6 months in older women (21) , but other clinical trials have not shown any relation between the initial leptin level and the subsequent weight change (22, 12) . Most of these studies have not adjusted for factors that could influence the weight reduction response.
Our third unexpected finding was that the hormonal starvation response was not or was only weakly related to the early changes in serum leptin. The negative energy balance resulted in the expected decreases in insulin (11) , TT 3 (23) , and leptin (3) and, at least in women, in the expected increase in cortisol (11) . However, the decrease in leptin levels was not related to the changes in cortisol or TT 3 and was only weakly related to the changes in insulin. These observations together with the fact that large early declines in leptin were associated with the largest and not the smallest long term weight reductions suggest that leptin by itself is of minor or no importance for the response to energy restriction in obese humans. These results are in contrast to those obtained in rodents, as discussed above. Besides the present study, there are additional indications that there may be species differences in the role of leptin as a starvation signal. Rodents without leptin display changes in the neuroendocrine system resembling those present during starvation. In contrast, humans with inactivating mutations in the genes encoding leptin and the leptin receptor have less severe endocrine disturbances (24 -27) . Furthermore, rodents without leptin have a reduced basal metabolic rate, in contrast to humans (27) . The regulation of the GH system in response to starvation further indicates the difference between humans and rodents. In man, GH secretion increases in response to starvation (28) , whereas it is blunted in rodents (29) . The decreased GH secretion in rodents is reversed by the administration of leptin (29) .
There are several limitations in this study. It was performed in 69 subjects only, and it may be that a larger number of subjects would have revealed more convincing relationships between the changes in insulin and those in serum leptin. On the other hand, the study was large enough to detect some highly significant relationships in both men and women, speaking against the importance of leptin as a regulator of the starvation response in obese subjects. Although confirming studies are needed, it is not likely that larger trials would arrive at opposite results. Another limitation could be that we may have chosen a nonoptimal timing for endocrine measurements. We cannot exclude this possibility. However, the fact that conclusions based on measurements at week 18, after 2 weeks of unchanged body weight, were similar to those based on examinations after 8 weeks of ongoing weight reduction, indicates that timing was not critical for our results. A third limitation is that our observations are based on serum leptin concentrations without taking possible changes in leptin sensitivity into consideration. Conclusions based on measurements of changes in serum leptin levels assume that leptin sensitivity is unaltered or is altered in an identical manner in all individuals included in the study. Experiments in rodents suggest that leptin sensitivity may be under hormonal and nutritional control (30, 31) . Thus, it might be that the relative lack of relations between changes in the serum levels of leptin and other endocrine variables could depend on alterations in leptin sensitivity in response to caloric restriction. As discussed above, this is not likely, because humans without leptin do not display a starvation-like endocrine pattern. However, our findings call for further analyses of basic aspects on the leptin system in humans, including studies of leptin sensitivity.
In conclusion, this study suggests that leptin by itself is not an important regulator of the starvation response in obese subjects. Taken together with previous reports on the relation between the leptin system and the starvation response in man, these results suggest that additional signals, yet to be identified, may act in concert with leptin in humans.
